employed in experimental animal models, and recently in clinical trials, to prevent or treat these immunologically induced diseases. However, the thrombotic events observed in some of the above studies raise important issues regarding future use of anti-CD154 antibodies in humans. In this study we demonstrate that a small interfering RNA (siRNA) can effectively reduce the surface expression of the human CD40 co-stimulatory receptor. Moreover, by rendering endothelial cells unresponsive to CD154+ Jurkat cell-mediated activation through RNA interference, induction of endothelial cell-adhesion molecule expression and leukocyte adhesion is prevented in vitro. Thus, anti-CD40 siRNA may become a safe and effective therapeutic option for interfering with CD40-CD154-mediated acute or chronic immuneinflammatory conditions. only.
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INTRODUCTION
The 48 kD type I transmembrane glycoprotein CD40 (TNFR5) holds a spectrum of signaling activities. Activation of endothelial cells via CD40-CD154 interaction triggers proinflammatory cytokine and chemokine production, matrix metalloproteinase and tissue factor expression, an increased density of leukocyte adhesion molecules CD62E, CD106 and CD54, and thrombomodulin downregulation. [1] [2] [3] [4] [5] [6] [7] These events play an important role in the promotion of extravasation and accumulation of activated T cells at the sites of inflammation.
Interruption of CD40 signaling is, thus, being considered as a potential pharmacological target for therapy. Indeed, pre-clinical studies in several animal models have shown that blockade of the CD40-CD154 pathway by antibodies to CD154 can prevent or treat a variety of autoimmune diseases, vascular disease and allograft rejection without inducing generalized immune suppression. 8 Remarkably, a recent clinical trial has demonstrated that passive administration of a humanized monoclonal antibody (mAb) specific for CD154 ameliorates disease in systemic lupus erythematosus (SLE) patients. 9 ,10 However, the association of anti-CD154 mAb therapy with thromboembolic complications in human and nonhuman primates has provoked concern, leading to a halt in all clinical studies using anti-CD154 antibodies.
10-
12 Thus, the development of alternative approaches to abrogate CD40-CD154 signaling seems mandatory for an effective and safer prevention or treatment of human immuneinflammatory disorders.
RNA interference (RNAi) mediated by small interfering RNAs (siRNA), a type of post-transcriptional gene silencing, is revolutionizing the field of functional genomics due to its powerful, sequence-specific capability to knockdown gene expression and shows great promise for therapeutic applications. 13 In this study, we demonstrate that efficient blockade of the CD40-CD154 signaling by RNAi-mediated silencing of human CD40 expression on vascular endothelial cells leads to inhibition of CD62E, CD106 and CD54 expression, and to with siRNA were performed to ensure maximum CD40 silencing on these primary cells.
RNA from siRNA-transfected cells was isolated and reverse transcribed (3 µg DNAse I-treated RNA/sample) using the RNeasy RNA Isolation and Omniscript RT kits (Qiagen). Quantification of CD40 mRNA levels was performed by real-time PCR using the LightCycler technology (Roche Molecular Biochemicals, Indianapolis, IN) and the human CD40-specific primers: CD40-f (5'-CAGCCAGGACAGAAACTGGTGAGT-3') and CD40-r (5'-CTTCTTCACAGGTGCAGATGGTGTC-3'). All samples were normalized using the following primer set for the constitutively expressed human cyclophilin gene: Cyph-f (5'-CTCCTTTGAGCTGTTTGCAG-3') and Cyph-r (5'-CACCACATGCTTGCCATCC-3'). 
RESULTS AND DISCUSSION

Selection and characterization of effective anti-CD40 siRNAs
Eight siRNAs were designed and generated by in vitro transcription to target defined positions within the coding region of the human CD40 mRNA ( Figure 1A ). The potencies of the eight siRNAs relative to a randomized control siRNA were compared at both the post- Figure 1C ). In terms of local target accessibility, the superior efficiency of the siRNA-2 over alternative siRNA designs may reflect its targeting toward a stable internal loop within the secondary structure of the CD40 mRNA, determined by suboptimal folding ( Figure 1D ). It is being progressively recognized that the activity of siRNAs, similarly to that of antisense oligonucleotides, is affected by the secondary structure of the target mRNA. 14, 15 only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From Interestingly, recent comparisons of the effectiveness of antisense oligonucleotides and siRNAs both in cell culture and in vivo suggest a superior efficiency and inhibitory persistence of the later. 16, 17 Moreover, siRNAs are highly effective without any chemical modifications, resulting in a dramatically lower toxicity profile compared with antisense oligomers.
Efficient blockade of CD40-CD154 signaling by anti-CD40 siRNA-2 mitigates proinflammatory events on human endothelial cells
CD40 receptor silencing by siRNA-2 in HUVEC was further recognized by immunoblotting ( Figure 1E ). Careful optimization of cationic lipid-mediated transfection of Cy3-labeled siRNAs on these cells yielded efficiencies in the range of 50% determined by fluorescence microscopy, with an acceptable toxicity (data not shown). This correlates with the moderate effect of siRNA-2, a 45 % inhibition of endogenous CD40 receptor expression, detected in TNF-/IFN--activated HUVEC.
A major step of the immune-mediated inflammatory process, endothelial cell activation via CD40-CD154 interaction, leads to induction of cell surface adhesion molecule expression, which orchestrate the egress of inflammatory cells from the vessel lumen.
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Thus, we investigated whether siRNA-2 could interfere with the CD40-CD154 activation pathway in HUVEC. We assessed the specific silencing effect of siRNA-2, compared with that of its corresponding mismatched control msiRNA-2, analyzing by flow cytometry both CAM expression and leukocyte adhesion in CD154-activated endothelial cells (Figure 2 ).
siRNA-2-treated, but not control msiRNA-2-treated, HUVEC showed a strong reduction of CAM expression when activated via CD154 (Figure 2A) . Moreover, direct evaluation of leukocyte adhesion on CD154-activated HUVEC using HL-60 cells, which express the ligands for all three adhesion molecules ICAM-1, VCAM-1, and E-selectin, demonstrated only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From that pre-treatment with siRNA-2, but not with msiRNA-2, reduced leukocyte adherence by 87 % (Figures 2B and 2C) . Furthermore, the anti-CD40 siRNA-2 had no effect on both CAM expression (data not shown) and leukocyte adhesion induced by TNF--mediated HUVEC activation ( Figure 2B ), demonstrating its inability to interfere with the family member CD120 (TNF-receptor), and hence its pathway specificity.
A recently completed pre-clinical trial has demonstrated the safety and efficacy of an siRNA therapeutic against vascular endothelial growth factor in a validated primate model of age-related macular degeneration. 18 The anti-CD40 siRNA is expected to have significant advantages over alternative approaches for CD40-CD154 co-stimulatory pathway blockade based on ligand/receptor binding, such as anti-CD40 or anti-CD154 antibodies, or the soluble CD40 form CD40Ig. 19 By activating the enzymatic RNAi mechanism, one anti-CD40 siRNA can destroy hundreds of targeted CD40 mRNA, which will result in the silencing of potentially thousands of CD40 protein receptors. Conversely, systemic administration of therapeutic antibodies or recombinant protein fusions may induce undesired immune responses against the foreign protein by the host, or result in serious side effects such as thromboembolism. 10, 20 The precise mechanism leading to the prothrombotic effects of anti-CD154 antibodies is not known, although it has been related either to inhibition of CD154-3 platelet integrin interaction 21 , or to their direct interaction with platelet Fc receptors. The anti-CD40 siRNA may become instrumental to discard the involvement of CD40 signaling in anti-CD154 antibody-mediated thromboembolism. In all, targeted delivery of anti-CD40
siRNA to specific CD40-expressing cells should avert the above-mentioned unwanted effects while exerting a powerful upstream downregulation of the CD40 pathway.
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